Luis Ibanez
Overview
Explore the profile of Luis Ibanez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ampuero J, Aller R, Gallego-Duran R, Crespo J, Calleja J, Garcia-Monzon C, et al.
J Gastroenterol
. 2024 Apr;
59(7):586-597.
PMID: 38619600
Background: MASLD can manifest as hepatocellular damage, which can result in mild elevation of aminotransferases. However, in some patients, MASLD presents with cholestatic pattern. Objective: To assess the impact of...
2.
Inzunza M, Irarrazaval M, Pozo P, Pimentel F, Crovari F, Ibanez L
Arq Bras Cir Dig
. 2023 May;
36:e1732.
PMID: 37162074
Background: Gallbladder polyps are becoming a common finding in ultrasound. The management has to consider the potential risk of malignant lesions. Aims: The aim of this study was to analyze...
3.
Rudler M, Hernandez-Gea V, Procopet B, Giraldez A, Amitrano L, Villanueva C, et al.
Gut
. 2022 Nov;
72(4):749-758.
PMID: 36328772
Background: A pre-emptive transjugular intrahepatic portosystemic shunt (pTIPS) reduces mortality in high-risk patients with cirrhosis (Child-Pugh C/B+active bleeding) with acute variceal bleeding (AVB). Real-life studies point out that <15% of...
4.
Bassegoda O, Olivas P, Turco L, Mandorfer M, Serra-Burriel M, Tellez L, et al.
Clin Gastroenterol Hepatol
. 2021 Oct;
20(10):2276-2286.e6.
PMID: 34688952
Background & Aims: Portal hypertension is the strongest predictor of hepatic decompensation and death in patients with cirrhosis. However, its discriminatory accuracy in patients with nonalcoholic fatty liver disease (NAFLD)...
5.
Carrillo C, Perello C, Llop E, Garcia-Samaniego J, Romero M, Mostaza J, et al.
Rev Esp Enferm Dig
. 2021 May;
113(11):780-786.
PMID: 33947196
Introduction: liver enzyme elevation has been reported in SARS-CoV-2 disease (COVID-19) in heterogeneous cohorts, mainly from China. Comprehensive reports from other countries are needed. In this study, we dissect the...
6.
Ampuero J, Aller R, Gallego-Duran R, Crespo J, Abad J, Gonzalez-Rodriguez A, et al.
Liver Int
. 2021 Apr;
41(9):2076-2086.
PMID: 33896100
Background And Aim: Histological score systems may not fully capture the essential nonalcoholic steatohepatitis (NASH) features, which is one of the leading causes of screening failure in clinical trials. We...
7.
Saavedra-Perez D, Curbelo-Pena Y, Sampson-Davila J, Albertos S, Serrano A, Ibanez L, et al.
Gastroenterol Hepatol
. 2021 Mar;
44(7):497-518.
PMID: 33647346
Symptomatic uncomplicated diverticular colon disease (SUDCD) is a highly prevalent disease in our setting, which significantly affects the quality of life of patients. Recent changes in understanding the natural history...
8.
Garcia Garcia de Paredes A, Manicardi N, Tellez L, Ibanez L, Royo F, Bermejo J, et al.
Hepatol Commun
. 2021 Feb;
5(2):309-322.
PMID: 33553977
Noninvasive staging of decompensated cirrhosis is an unmet clinical need. The aims of this study were to characterize and validate a novel microRNA (miRNA) signature to stage decompensated cirrhosis and...
9.
Ampuero J, Aller R, Gallego-Duran R, Crespo J, Calleja J, Garcia-Monzon C, et al.
J Hepatol
. 2020 Jul;
73(3):740-741.
PMID: 32654856
No abstract available.
10.
Ampuero J, Aller R, Gallego-Duran R, Crespo J, Calleja J, Garcia-Monzon C, et al.
J Hepatol
. 2020 Mar;
73(1):17-25.
PMID: 32147361
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) could play a catalytic role in the development of metabolic comorbidities, although the magnitude of this effect in metabolically healthy patients with...